Findings showed fenebrutinib significantly reduced relapses vs teriflunomide in RMS and was noninferior to ocrelizumab in slowing disability progression in PPMS. Topline data were announced from two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results